Literature DB >> 15657365

Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation.

Ilan Ifergan1, Gerrit Jansen, Yehuda G Assaraf.   

Abstract

The unique capability of breast cancer resistance protein (BCRP/ABCG2) to export mono-, di-, and triglutamates of folates should limit cellular proliferation under conditions of folate deprivation, particularly upon BCRP overexpression. Here, we explored the mode of adaptation of BCRP-overexpressing cells to short-term folate deprivation. MCF-7/MR cells grown in high folate medium (2.3 muM folic acid) containing mitoxantrone had 62% of their overexpressed BCRP in the plasma membrane and only 38% in the cytoplasm. In contrast, cells grown for 2 weeks in folic acid-free medium followed by an adaptation week in low folate medium (1 nM folic acid) had 86% of BCRP in the cytoplasm and only 14% in the plasma membrane. Unlike BCRP, various transmembrane proteins retained their normal plasma membrane localization in folate-deprived cells. Folate deprivation was also associated with a 3-fold decrease in BCRP and multidrug resistance protein 1 (MRP1/ABCC1) levels. Confocal microscopy with folate-deprived cells revealed that cytoplasmic BCRP colocalized with calnexin, an established endoplasmic reticulum resident. The loss of BCRP from the plasma membrane in folate-deprived cells consistently resulted in a 4.5-fold increase in [(3)H]folic acid accumulation relative to MCF-7/MR cells. Hence, cellular adaptation to shortterm folate deprivation results in a selective confinement of BCRP to the cytoplasm along with a moderate decrease in BCRP and MRP1 levels aimed at preserving the poor intracellular folate pools. These results constitute a novel mechanism of cellular adaptation to short-term folate deprivation and provide further support to the possible role of BCRP in the maintenance of cellular folate homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657365     DOI: 10.1124/mol.104.008250

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Mechanisms of membrane transport of folates into cells and across epithelia.

Authors:  Rongbao Zhao; Ndeye Diop-Bove; Michele Visentin; I David Goldman
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

Review 2.  The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.

Authors:  Larry H Matherly; Zhanjun Hou; Aleem Gangjee
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-10       Impact factor: 3.333

3.  Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.

Authors:  Sita Kugel Desmoulin; Lei Wang; Lisa Polin; Kathryn White; Juiwanna Kushner; Mark Stout; Zhanjun Hou; Christina Cherian; Aleem Gangjee; Larry H Matherly
Journal:  Mol Pharmacol       Date:  2012-06-26       Impact factor: 4.436

4.  The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis.

Authors:  Ilan Ifergan; Gerrit Jansen; Yehuda G Assaraf
Journal:  J Biol Chem       Date:  2008-05-22       Impact factor: 5.157

5.  Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.

Authors:  Benny Zhitomirsky; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-11

Review 6.  The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.

Authors:  Sita Kugel Desmoulin; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

Review 7.  Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.

Authors:  C Lemos; G Jansen; G J Peters
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

8.  Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency.

Authors:  Zhanjun Hou; Steve Orr; Larry H Matherly
Journal:  Biosci Rep       Date:  2014-08-06       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.